Takasaki

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at high risk. This Phase 3 trial enrolls about 4,500 adults with MASLD identified by non-invasive tests indicating an increased likelihood of developing serious liver problems. The study aims to understand how these treatments might affect liver health over time compared to a placebo. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, during which participants may attend 25 to 30 clinic visits for monitoring and assessment. After the main study, eligible participants can join an optional 2-year extension where all will receive either retatrutide or tirzepatide regardless of their original group. Throughout the trial, participants’ liver function and disease progression will be closely monitored through various health assessments. Researchers will track the time to the first major adverse liver event as the main outcome. Safety and health status will be evaluated regularly during clinic visits, ensuring thorough observation over the long study period.

Researchers are evaluating the safety and effectiveness of astegolimab compared to a placebo in adults aged 40 to 80 years who have chronic obstructive pulmonary disease (COPD). The study focuses on participants who are former or current smokers with a history of frequent COPD flare-ups. This phase III trial aims to determine how well astegolimab reduces moderate and severe COPD exacerbations over one year. Participants will be randomly assigned to receive either subcutaneous astegolimab every two or four weeks or a placebo every two weeks. All participants will continue their optimized COPD maintenance treatments, which may include combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonists. Study treatments will be administered over a 52-week period. Throughout the study, researchers will monitor the annual rate of moderate and severe COPD exacerbations. Participants will undergo lung function tests, chest imaging, and assessments of breathlessness and lung health. The study will also carefully track the safety of the treatments, including any infections or heart-related problems. The total participation time is 52 weeks, during which the effectiveness and safety of astegolimab will be evaluated.

Researchers are evaluating the safety and effects of ritlecitinib for treating chronic spontaneous urticaria (CSU) in adults whose condition is not well controlled by antihistamines. CSU causes itchy hives and swelling under the skin without a clear cause. This Phase 2b study compares two oral doses of ritlecitinib, 50 mg and 100 mg, with a placebo to understand if these doses are safe and effective in managing symptoms. Participants will be randomly assigned to take either 50 mg, 100 mg, or placebo capsules once daily for 12 weeks (Period A). After this, those on ritlecitinib will continue their assigned dose while those on placebo will switch to 100 mg for another 12 weeks (Period B). The study involves about 150 adult participants and compares the effects of the two ritlecitinib doses against placebo over these two 12-week periods. Participants will be involved in the study for about 8 months with up to 9 visits to the study site. During visits, they will have physical exams, hearing tests, blood tests, X-rays, and ECGs. They will also complete daily questionnaires about their urticaria symptoms using an electronic diary. Researchers will measure changes in urticaria activity and monitor for any treatment-related side effects or adverse events throughout the study.

Researchers are investigating the effects of starting finerenone treatment early during hospitalization for patients with acute heart failure who have a left ventricular ejection fraction of 40% or higher. This Phase 4, multicenter, randomized, double-blind, placebo-controlled trial aims to assess whether early use of finerenone can improve outcomes in this patient group. Participants are randomly assigned to receive either finerenone or a matching placebo tablet. The finerenone dosing depends on kidney function: patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m² or less start at 10 mg once daily, with a maximum dose of 20 mg once daily; those with eGFR above 60 mL/min/1.73 m² start at 20 mg once daily, with a maximum dose of 40 mg once daily. Treatment begins within 36 hours after hospital admission, with randomization occurring within 24 hours. During the study, participants will be monitored for up to 12 weeks to evaluate a combined outcome of death and worsening heart failure. Researchers will conduct assessments including physical exams, symptom evaluation, laboratory tests, and heart function measurements. Safety and adherence to treatment will be tracked throughout the study, ensuring comprehensive evaluation of the therapy's impact during the critical early phase of hospitalization.